Compare NXST & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXST | TVTX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.7B |
| IPO Year | 2002 | 2013 |
| Metric | NXST | TVTX |
|---|---|---|
| Price | $196.51 | $47.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $245.38 | $73.43 |
| AVG Volume (30 Days) | 348.8K | ★ 1.9M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 16.62 | N/A |
| Revenue | ★ $4,949,000,000.00 | N/A |
| Revenue This Year | $60.76 | $55.96 |
| Revenue Next Year | N/A | $48.63 |
| P/E Ratio | $12.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $153.17 | $22.59 |
| 52 Week High | $254.30 | $68.73 |
| Indicator | NXST | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 35.71 |
| Support Level | $175.53 | $41.75 |
| Resistance Level | $198.56 | $48.60 |
| Average True Range (ATR) | 7.85 | 2.55 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 60.62 | 29.52 |
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Assuming its merger with Tegna is affirmed, Nexstar's station total would exceed 259 and reach 80% of the US population. Nexstar also owns NewsNation (formerly WGN America), a cable news network, 75% of the fifth national broadcaster, The CW, and a 31% stake in Food Network and Cooking Channel.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.